Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Natco Pharma announced the launch of Carboplatin Injection, a generic version of Paraplatin® in the U.S. market by its U.S. subsidiary NATCO Pharma USA LLC.
Natco has launched this product in manufacturing collaboration with Teyro Labs, based in Chennai.
This launch helps address a critical shortage of the product in the U.S. market. Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy.
Carboplatin Injection had estimated sales of USD 27.8 million in the U.S. for 12 months ending June'26 as per industry sales data.
Natco Pharma is investing US$ 14 million in eGenesis, Inc. through its wholly owned subsidiaries, NATCO Pharma (Canada) Inc. for an amount of US$ 9.5 million and NATCO Pharma South Africa Proprietary for an amount of US$ 4.5 million, though convertible promissory notes. Previously in 2024, NATCO Pharma had invested US$ 8 million in eGenesis, Inc. through preferred stock. The total investment made by NATCO Pharma in eGenesis, Inc. now stands at US$ 22 million.
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure. The eGenesis Genome Engineering and Production (EGEN™) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant. eGenesis is advancing development programs for kidney transplant, acute liver failure, and heart transplant.
In March 2024, eGenesis announced the world's first porcine kidney transplant in a living patient. The transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway. It was followed by porcine kidney transplants in additional two patients. The outcomes have been exceptionally positive.
Shares of Steel Authority of India (SAIL) barred from fresh F&O positions on 24 August 2026.
New Listings:
Horizon Industrial Parks will list on the bourses. The IPO was subscribed 1.52 times, receiving bids for 36.37 crore shares against 25.13 crore shares on offer.
Lalithaa Jewellery Mart will also list on the stock exchanges. The IPO was subscribed 62.97 times, with the offer receiving bids for 395.22 crore shares against 6.27 crore shares on offer.
Stocks To Watch:
Caplin Point Laboratories announced that the US Food and Drug Administration (USFDA) conducted an unannounced inspection of its subsidiary Caplin Steriles’ injectable and ophthalmic manufacturing facility in Gummidipoondi, Tamil Nadu.
Federal Bank announced that its board has approved a proposal to raise up to $ 500 million through the issuance of foreign currency-denominated bonds via its IFSC Banking Unit (IBU) at GIFT City.
Manipal Health Enterprises reported a 7.48% decline in consolidated net profit to Rs 231.65 crore in Q1 FY27 from Rs 250.37 crore in Q1 FY26, despite strong growth in revenue and operating performance. Revenue from operations increased 38.12% year-on-year to Rs 3,090.63 crore during the quarter.
B.R.Goyal Infrastructure announced that it has received a work order worth Rs 151.06 crore from the National Highways Authority of India (NHAI) for engagement of a user fee agency through e-Tender at Jajau Fee Plaza in Madhya Pradesh.
NATCO Pharma said that the U.S. Food and Drug Administration (US FDA) has issued a Form 483 with four observations post an inspection to the company's manufacturing plant at Visakhapatnam.
Mamata Machinery said that the company has been granted a patent in India for the technology used in its Quadra 600 machine.
Upon conclusion of the inspection, the Company has been issued a Form 483 with 4 (Four) observations.
In a regulatory filing made post market hours yesterday, the pharmaceutical major said that the US FDA had conducted an inspection at the company’s FDF manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh, India, which was conducted from 17th August 2026 to 21st August 2026.
Upon conclusion of the inspection, the c ompany has been issued a Form 483 with four observations.
'The company believes that the observations are procedural in nature and is confident of addressing these observations comprehensively within stipulated timelines,' NATCO Pharma said in a statement.
NATCO Pharma develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products.
The company's consolidated net profit declined 57.04% to Rs 206.50 crore on a 44.68% fall in revenue to Rs 735.20 crore in Q1 FY27 as compared to Q1 FY26.
The scrip had risen 0.54% to end at Rs 882.50 on the BSE on Friday.